Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04438382 | Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis | terminated | Phase 2 | 1 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05629689 | A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies | terminated | Phase 1 | 19 | GE HealthcareINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05477784 | Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With Advanced Cancer and Their Children(EC-PC) | terminated | N/A | 174 | University of WashingtonOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | SystImmune Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00801151 | Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer | terminated | Phase 1 | 30 | Institut Claudius RegaudOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05052255 | RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 66 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT03585465 | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors(Metro-PD1) | terminated | Phase 1 / Phase 2 | 63 | Centre Oscar LambretOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 429 | GenmabINDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | terminated | Phase 1 | 23 | GenmabINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06039384 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | terminated | Phase 1 | 6 | Incyte CorporationINDUSTRY | 4 | Sep 8, 2026 | clinicaltrials |
| NCT06873789 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | Incyte CorporationINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04249843 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | terminated | Phase 1 | 109 | MapKure, LLCINDUSTRY | 2 | Aug 31, 2026 | clinicaltrials |
| NCT06438588 | Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial | terminated | N/A | 2 | Mayo ClinicOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06171178 | A Study of ASP1012 in Adults With Solid Tumors | terminated | Phase 1 | 15 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05718219 | Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors | terminated | Phase 1 | 49 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05580770 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 23 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | terminated | Phase 1 | 226 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 14, 2026 | clinicaltrials |
| NCT05101213 | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | terminated | Phase 1 / Phase 2 | 21 | GenmabINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | terminated | Phase 1 / Phase 2 | 3 | Tianhong LiOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | terminated | Phase 1 | 45 | Nuvectis Pharma, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT05307874 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors(EVICTION-2) | terminated | Phase 1 / Phase 2 | 56 | ImCheck Therapeutics, an Ipsen companyINDUSTRY | 3 | Jul 30, 2026 | clinicaltrials |
| NCT05826600 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | terminated | Phase 1 / Phase 2 | 68 | iOmx Therapeutics AGINDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT06929260 | A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z | terminated | Phase 1 | 1 | AstraZenecaINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06008483 | A Dose Finding Study to Treat Bone Tumor(s) | terminated | Phase 1 | 5 | QSAM Therapeutics, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 38 | Antengene Biologics LimitedINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06364696 | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | terminated | Phase 1 | 60 | Astellas Pharma IncINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06685068 | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 23 | GenmabINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | terminated | Phase 1 | 47 | BeOne MedicinesINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT05164666 | A Study of TAK-103 in Adult With Solid Tumors | terminated | Phase 1 | 2 | TakedaINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 41 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05525247 | A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | terminated | Phase 1 / Phase 2 | 27 | SelecxineINDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT05109975 | A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors | terminated | Phase 1 | 93 | Debiopharm International SAINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-301) | terminated | Phase 1 / Phase 2 | 260 | AmgenINDUSTRY | 26 | Jun 22, 2026 | clinicaltrials |
| NCT06035744 | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | terminated | Phase 1 | 23 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05159388 | A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | Servier Bio-Innovation LLCINDUSTRY | 4 | Jun 16, 2026 | clinicaltrials |
| NCT06188208 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | terminated | Phase 1 | 132 | Vividion Therapeutics, Inc.INDUSTRY | 3 | Jun 12, 2026 | clinicaltrials |
| NCT06299761 | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications(STARMAP) | terminated | Phase 1 | 19 | Boundless Bio, Inc.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04800822 | PF-07284892 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 53 | PfizerINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05949632 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Incyte CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04303858 | A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 | 189 | Hoffmann-La RocheINDUSTRY | 5 | Jun 2, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05571969 | Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors | terminated | Phase 1 | 14 | Allarity TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06465017 | ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer | terminated | N/A | 149 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07082257 | Precision Performance Status Compared With ECOG Performance Status | terminated | — | 41 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05839600 | A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer | terminated | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 4 | May 22, 2026 | clinicaltrials |
Data updated 3 hours agoSource updated Sep 29, 2026source: clinicaltrials